Aarti Drugs Limited (AARTIDRUGS)
Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-term Strategic Growth
Board approved elevation of Shri Rashesh C. Gogri to Chairman and appointment of Shri Adhish P. Patil as Managing Director, effective October 1, 2026. Shri Prakash M. Patil to retire as Chairman, MD & CEO on September 30, 2026, continuing as advisor for smooth transition. Leadership change aims to strengthen governance and support long-term strategic growth while preserving institutional knowledge and expertise.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AARTIDRUGS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AARTIDRUGS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aarti Drugs Limited
Important.
The summary above is generated automatically from Aarti Drugs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.